These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 9029059

  • 1. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi K, Watabe T, Ogura Y.
    Drug Metab Dispos; 1997 Feb; 25(2):270-3. PubMed ID: 9029059
    [Abstract] [Full Text] [Related]

  • 2. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y, Watabe T.
    Drug Metab Dispos; 1997 May; 25(5):270-3. PubMed ID: 9152608
    [Abstract] [Full Text] [Related]

  • 3. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H, Ogura K, Kato A, Takubo H, Watabe T.
    J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
    [Abstract] [Full Text] [Related]

  • 4. [Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil].
    Watabe T, Okuda H, Ogura K.
    Yakugaku Zasshi; 1997 Nov; 117(10-11):910-21. PubMed ID: 9414600
    [Abstract] [Full Text] [Related]

  • 5. [Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].
    Watabe T, Ogura K, Nishiyama T.
    Yakugaku Zasshi; 2002 Aug; 122(8):527-35. PubMed ID: 12187768
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil.
    Kanamitsu SI, Ito K, Okuda H, Ogura K, Watabe T, Muro K, Sugiyama Y.
    Drug Metab Dispos; 2000 Apr; 28(4):467-74. PubMed ID: 10725316
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
    Cao S, Baccanari DP, Joyner SS, Davis ST, Rustum YM, Spector T.
    Cancer Res; 1995 Dec 15; 55(24):6227-30. PubMed ID: 8521418
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kuritani J.
    Clin Cancer Res; 1998 Sep 15; 4(9):2085-8. PubMed ID: 9748123
    [Abstract] [Full Text] [Related]

  • 13. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K, Masuda H, Matsushima E, Ikeda K, Nagayama S, Kawaguchi Y.
    Drug Metab Dispos; 2000 Oct 15; 28(10):1162-7. PubMed ID: 10997934
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ, Noordhuis P, Van Kuilenburg AB, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ.
    Cancer Chemother Pharmacol; 2003 Jul 15; 52(1):1-12. PubMed ID: 12739060
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS, Hammond LA, Schwartz G, Ochoa L, Rha SY, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK.
    Clin Cancer Res; 2004 Aug 01; 10(15):4913-21. PubMed ID: 15297391
    [Abstract] [Full Text] [Related]

  • 20. [Pharmacokinetics of S-1].
    Hirata K, Horikoshi N, Tominaga K, Sohma K, Yamaguchi K, Okazaki M, Furuhata T, Sasaki K, Nakano Y, Ishizuka H, Yamada Y, Uno S, Taguchi T, Yamamitsu S, Shirasaka T.
    Gan To Kagaku Ryoho; 2006 Jun 01; 33 Suppl 1():27-35. PubMed ID: 16897969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.